ZNTL

Zentalis is a pre-revenue, clinical-stage biopharma whose entire value rests on one molecule: azenosertib, a WEE1 inhibitor being advanced in Cyclin E1-positive platinum-resistant ovarian cancer. There is no commercial business to analyze — FY2025 revenue was $0.00 (the $67.4M booked in FY2024, presumably a partnership/milestone, evaporated to nothing, hence the -100% print), and the company plainly states in its 10-K that it has 'no products approved for commercial sale' and expects 'it will be several years, if ever, before we have a commercialized product.' The accumulated deficit is $1.2B and FY2025 net loss was -$137M. This is a lottery ticket on a Phase 2 trial, not an ownable operating company, and my framework rates unknowable, single-outcome risk as 'avoid.'

The balance sheet is the sharper worry. Reported cash & equivalents are just $36M, and while total current assets of $253M (the rest is marketable securities) cushion that, operating cash flow was -$125M in FY2025. Even on the broader liquidity base, that is roughly 1.5–2 years of runway before another raise — and the company confirms it has historically financed itself 'through private financings, our IPO, and follow-on public offerings of our common stock.' With shares at $4.46 (near book value of ~$3.05/share on $216M equity ÷ 70.9M shares) and a ~$316M market cap, any dilutive raise before the readout would hit existing holders hard. R&D spend already fell -36% YoY to $107M, which extends runway but also signals a company narrowing its bets rather than expanding — consistent with an all-in push toward DENALI.